These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9917494)

  • 1. Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures.
    Schirrmacher V; Jurianz K; Roth C; Griesbach A; Bonifer R; Zawatzky R
    Int J Oncol; 1999 Feb; 14(2):205-15. PubMed ID: 9917494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta.
    von Hoegen P; Zawatzky R; Schirrmacher V
    Cell Immunol; 1990 Mar; 126(1):80-90. PubMed ID: 2302742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response.
    Von Hoegen P; Weber E; Schirrmacher V
    Eur J Immunol; 1988 Aug; 18(8):1159-66. PubMed ID: 2970967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects.
    Schirrmacher V; Griesbach A; Ahlert T
    Int J Oncol; 2001 May; 18(5):945-52. PubMed ID: 11295039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
    Schirrmacher V; Haas C; Bonifer R; Ertel C
    Clin Cancer Res; 1997 Jul; 3(7):1135-48. PubMed ID: 9815793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation.
    Schild H; von Hoegen P; Schirrmacher V
    Cancer Immunol Immunother; 1989; 28(1):22-8. PubMed ID: 2462467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells.
    Termeer CC; Schirrmacher V; Bröcker EB; Becker JC
    Cancer Gene Ther; 2000 Feb; 7(2):316-23. PubMed ID: 10770642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus.
    Haas C; Ertel C; Gerhards R; Schirrmacher V
    Int J Oncol; 1998 Dec; 13(6):1105-15. PubMed ID: 9824618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy.
    Xu X; Sun Q; Yu X; Zhao L
    Virus Res; 2017 Apr; 233():35-41. PubMed ID: 28286036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of lymphocyte mitogenesis in mice infected with Newcastle disease virus: viral interference with the interleukin system.
    Colonna Romano G; Dieli F; Abrignani S; Salerno A; Colizzi V
    Immunology; 1986 Mar; 57(3):373-8. PubMed ID: 2937717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral hemagglutinin augments peptide-specific cytotoxic T cell responses.
    Ertel C; Millar NS; Emmerson PT; Schirrmacher V; von Hoegen P
    Eur J Immunol; 1993 Oct; 23(10):2592-6. PubMed ID: 8405059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antitumor research on mouse melanoma with combined application of Newcastle disease virus and its HN gene].
    Mi ZQ; Jin NY; Sun YC; Li X; Lian H; Li J; Guan GF
    Ai Zheng; 2004 Aug; 23(8):910-3. PubMed ID: 15301713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
    Fournier P; Bian H; Szeberényi J; Schirrmacher V
    Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically engineered Newcastle disease virus for malignant melanoma therapy.
    Zamarin D; Vigil A; Kelly K; García-Sastre A; Fong Y
    Gene Ther; 2009 Jun; 16(6):796-804. PubMed ID: 19242529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC).
    Palmer KJ; Harries M; Gore ME; Collins MK
    Clin Exp Immunol; 2000 Mar; 119(3):412-8. PubMed ID: 10691911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.
    Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C
    Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STUDIES ON PERSISTENT INFECTIONS OF TISSUE CULTURES. V. THE INITIAL STAGES OF INFECTION OF L(MCN) CELLS BY NEWCASTLE DISEASE VIRUS.
    RODRIGUEZ JE; HENLE W
    J Exp Med; 1964 Jan; 119(6):895-921. PubMed ID: 14178459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration.
    Phuangsab A; Lorence RM; Reichard KW; Peeples ME; Walter RJ
    Cancer Lett; 2001 Oct; 172(1):27-36. PubMed ID: 11595126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response.
    Zhao L; Mei Y; Sun Q; Guo L; Wu Y; Yu X; Hu B; Liu X; Liu H
    J Immunol; 2014 Jul; 193(2):735-45. PubMed ID: 24943214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor-specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals.
    von Hoegen P; Heicappell R; Griesbach A; Altevogt P; Schirrmacher V
    Invasion Metastasis; 1989; 9(2):117-33. PubMed ID: 2785093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.